Latara Enterprise INC.

Latara Enterprise INC. was paid $61.65M by Medicaid between Jan 2018 and Dec 2024, across 349 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 9.8% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#16 of 561

Median peer was paid$222K

This provider vs. median278×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	880,144	$7.06M
2019	1,028,435	$6.76M
2020	1,010,923	$7.52M
2021	1,376,615	$11.65M
2022	1,532,762	$9.71M
2023	1,765,099	$9.61M
2024incomplete	1,705,991	$9.35M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	9.8%	88,991	69,032	$6.07M
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	9.3%	305,379	290,817	$5.70M
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	6.7%	303,163	288,796	$4.15M
87806		4.3%	239,905	222,363	$2.67M
84443	Thyroid stimulating hormone (TSH)	3.9%	503,045	494,430	$2.42M
80053	Comprehensive metabolic panel	3.7%	666,154	643,538	$2.27M
86003		3.5%	29,731	27,285	$2.13M
80061	Lipid panel	3.4%	570,279	563,166	$2.07M
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	3.3%	259,776	256,653	$2.04M
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	3.2%	13,830	13,772	$1.97M
86481		3.1%	32,005	31,813	$1.93M
85025	Blood count; complete (CBC), automated, and automated differential WBC count	2.7%	730,624	702,259	$1.68M

337 more codes

83036	Hemoglobin; glycosylated (A1C)	2.7%	572,124	$1.64M
80081		2.5%	24,824	$1.51M
88305	Level IV - Surgical pathology, gross and microscopic examination	2.2%	21,661	$1.33M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	2.1%	78,173	$1.30M
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	2.1%	64,255	$1.27M
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	1.5%	42,450	$899K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	1.3%	77,796	$807K
80074		1.2%	76,842	$748K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	1.1%	16,111	$679K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	35,358	$483K
87086	Culture, bacterial; quantitative colony count, urine	<1%	183,480	$482K
86592		<1%	210,544	$478K
86235		<1%	13,911	$473K
82607		<1%	111,169	$437K
86696		<1%	42,679	$431K
86803		<1%	66,575	$415K
36415	Collection of venous blood by venipuncture	<1%	250,543	$405K
80055		<1%	22,611	$339K
81001		<1%	426,990	$329K
86695		<1%	37,843	$300K
84702		<1%	46,900	$290K
81513		<1%	4,527	$285K
84439		<1%	146,939	$284K
82728		<1%	62,529	$242K
84403		<1%	30,669	$240K
84153		<1%	56,092	$237K
87522	Neg quan hep c or qual rna	<1%	9,575	$229K
83655		<1%	49,539	$224K
84481		<1%	49,829	$216K
83540		<1%	89,286	$208K
83550		<1%	73,685	$196K
82746		<1%	59,611	$193K
88313		<1%	4,773	$192K
87186		<1%	60,520	$184K
82043		<1%	141,731	$183K
88312		<1%	5,465	$175K
87480		<1%	16,142	$171K
86038		<1%	53,410	$170K
84436		<1%	115,258	$169K
82570		<1%	112,233	$163K
86480		<1%	22,566	$159K
83735		<1%	51,666	$149K
84480		<1%	20,338	$148K
82652		<1%	24,966	$148K
86160		<1%	16,663	$145K
87510		<1%	16,136	$141K
87660		<1%	16,081	$140K
80050	General health panel	<1%	28,186	$137K
86704		<1%	33,139	$137K
82785		<1%	16,056	$135K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	3,004	$133K
P9011	Blood, split unit	<1%	7,645	$132K
86376		<1%	22,933	$131K
86901		<1%	25,254	$129K
83970		<1%	12,649	$126K
86635		<1%	5,993	$126K
86769		<1%	5,127	$125K
82951		<1%	16,033	$124K
84550		<1%	83,308	$122K
87209		<1%	9,591	$119K
84479		<1%	85,994	$119K
87536		<1%	2,907	$117K
83013		<1%	5,122	$116K
82274		<1%	13,219	$115K
86317		<1%	22,997	$113K
87902		<1%	917	$113K
86431		<1%	54,498	$109K
86200		<1%	20,717	$107K
87481		<1%	4,241	$105K
80048	Basic metabolic panel (calcium, ionized)	<1%	47,600	$103K
82670		<1%	13,708	$101K
87081		<1%	26,821	$95K
87340		<1%	26,741	$95K
83880		<1%	9,894	$94K
87338		<1%	19,240	$92K
86225		<1%	16,745	$92K
88185		<1%	411	$90K
86708		<1%	24,342	$88K
86787		<1%	14,951	$87K
85652		<1%	86,331	$87K
84270		<1%	14,930	$87K
86140		<1%	54,695	$85K
83001		<1%	22,105	$82K
87070		<1%	39,711	$81K
82950		<1%	34,392	$77K
88342		<1%	1,810	$65K
83002		<1%	17,289	$64K
84154		<1%	18,335	$64K
87177		<1%	9,606	$59K
80076		<1%	30,630	$58K
82947		<1%	28,993	$57K
88142		<1%	5,342	$56K
86706		<1%	17,791	$56K
86780		<1%	8,950	$54K
82105		<1%	5,098	$49K
84146		<1%	14,497	$48K
88141		<1%	9,089	$47K
86900		<1%	17,540	$42K
84100		<1%	23,382	$40K
88341		<1%	487	$40K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	154	$38K
85610		<1%	45,176	$37K
83525		<1%	8,669	$37K
83021		<1%	6,473	$35K
87088		<1%	14,254	$34K
82248		<1%	31,450	$34K
84144		<1%	7,256	$32K
86762		<1%	9,825	$32K
83516		<1%	10,161	$31K
84681		<1%	5,178	$30K
85027		<1%	25,511	$29K
87210		<1%	12,529	$29K
85730		<1%	37,462	$28K
84445		<1%	2,329	$27K
82977		<1%	11,117	$27K
87625		<1%	1,624	$26K
86255		<1%	7,130	$24K
83690		<1%	13,700	$24K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	184	$22K
86812		<1%	2,090	$21K
86800		<1%	6,325	$21K
82784		<1%	7,004	$21K
84156		<1%	17,155	$21K
86677		<1%	7,854	$21K
86141		<1%	8,979	$20K
88112		<1%	1,093	$19K
82550		<1%	12,069	$19K
83090		<1%	2,918	$19K
82150		<1%	11,696	$16K
88304		<1%	677	$16K
86341		<1%	898	$16K
82378		<1%	8,779	$16K
86735		<1%	7,557	$15K
86147		<1%	1,450	$15K
83695		<1%	2,347	$15K
82952		<1%	8,016	$15K
86665		<1%	2,244	$15K
87517		<1%	583	$15K
86039		<1%	3,564	$14K
86765		<1%	7,865	$14K
86694		<1%	2,604	$14K
82627		<1%	5,187	$14K
83014		<1%	5,120	$13K
85007		<1%	22,929	$13K
86360		<1%	1,959	$13K
88184		<1%	411	$13K
82270		<1%	33,852	$13K
82533		<1%	3,028	$12K
81329		<1%	133	$12K
86593		<1%	6,255	$12K
82671		<1%	2,343	$12K
88189		<1%	395	$11K
82247		<1%	4,369	$11K
86304		<1%	4,907	$11K
83520		<1%	2,722	$11K
86359		<1%	1,961	$11K
87045		<1%	4,834	$11K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	318	$11K
84703		<1%	9,756	$11K
87255		<1%	1,681	$10K
82140		<1%	1,878	$9K
86850		<1%	5,597	$9K
86146		<1%	618	$9K
82239		<1%	1,288	$8K
86301		<1%	3,058	$8K
86300		<1%	4,908	$8K
84484		<1%	1,548	$8K
87328		<1%	1,005	$8K
82465		<1%	9,606	$8K
88164		<1%	795	$8K
81270		<1%	199	$8K
80159		<1%	877	$7K
86060		<1%	2,107	$7K
87581		<1%	154	$7K
87329		<1%	1,196	$7K
86335		<1%	474	$7K
88360		<1%	79	$7K
84425		<1%	1,410	$7K
82172		<1%	2,217	$7K
84165		<1%	3,214	$7K
86885		<1%	2,775	$7K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	709	$7K
84466		<1%	1,020	$6K
82040		<1%	11,255	$6K
86308		<1%	1,338	$6K
84305		<1%	1,219	$6K
83615		<1%	12,225	$6K
82565		<1%	5,218	$6K
80069		<1%	3,010	$6K
86645		<1%	724	$6K
87800		<1%	282	$6K
83883		<1%	2,584	$6K
82103		<1%	1,472	$5K
81025		<1%	4,744	$5K
87077		<1%	2,737	$5K
83993		<1%	1,428	$5K
86705		<1%	2,958	$5K
87563		<1%	285	$5K
83721		<1%	7,070	$4K
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	1,120	$4K
84166		<1%	435	$4K
86710		<1%	172	$4K
83010		<1%	2,790	$4K
85045		<1%	5,448	$4K
82024		<1%	856	$4K
83498		<1%	1,097	$4K
80164		<1%	1,810	$4K
85613		<1%	1,319	$4K
82390		<1%	1,387	$3K
85014		<1%	6,118	$3K
86644		<1%	1,005	$3K
85379		<1%	1,788	$3K
85018		<1%	10,556	$3K
87324		<1%	1,372	$3K
82330		<1%	698	$3K
82088		<1%	379	$3K
86337		<1%	199	$3K
84207		<1%	444	$3K
80197		<1%	956	$3K
84460		<1%	6,200	$2K
86331		<1%	206	$2K
87632		<1%	16	$2K
86632		<1%	74	$2K
86682		<1%	232	$2K
86709		<1%	1,173	$2K
83527		<1%	308	$2K
86036		<1%	501	$2K
84450		<1%	6,404	$2K
86171		<1%	237	$2K
84432		<1%	767	$2K
82397		<1%	258	$2K
82310		<1%	3,390	$2K
86334		<1%	874	$2K
86738		<1%	144	$2K
80177		<1%	878	$2K
84482		<1%	121	$2K
84182		<1%	27	$2K
84132		<1%	1,470	$1K
84402		<1%	84	$1K
85245		<1%	524	$1K
81243		<1%	30	$1K
82668		<1%	985	$1K
80051		<1%	1,124	$1K
84145		<1%	89	$1K
85240		<1%	611	$1K
82300		<1%	88	$1K
85660		<1%	1,793	$1K
82085		<1%	595	$1K
88262		<1%	12	$1K
83921		<1%	736	$1K
85246		<1%	507	$1K
88230		<1%	12	$1K
84134		<1%	562	$1K
82175		<1%	88	$1K
84630		<1%	488	$990.96
84080		<1%	445	$984.31
84244		<1%	263	$944.72
86702		<1%	277	$917.39
83605		<1%	137	$906.30
87040		<1%	111	$817.09
82626		<1%	341	$810.48
82107		<1%	91	$807.10
84520		<1%	1,938	$799.99
83825		<1%	89	$792.94
85060		<1%	1,092	$760.96
82157		<1%	67	$703.06
84155		<1%	2,673	$687.76
82525		<1%	332	$643.27
86701		<1%	290	$603.72
84478		<1%	2,334	$565.29
87350		<1%	89	$551.28
85384		<1%	676	$524.09
87535		<1%	24	$520.31
87341		<1%	280	$491.61
81207		<1%	12	$459.84
84075		<1%	963	$447.16
83718		<1%	633	$411.37
86256		<1%	288	$364.88
84260		<1%	12	$305.75
87205		<1%	533	$304.72
80185		<1%	221	$295.76
87799		<1%	15	$291.88
85670		<1%	198	$277.20
87254		<1%	194	$275.10
82308		<1%	12	$261.91
80178		<1%	371	$230.58
83835		<1%	93	$212.70
86671		<1%	133	$207.72
82985		<1%	414	$201.59
83018		<1%	12	$195.20
86148		<1%	51	$166.26
82575		<1%	45	$152.08
83789		<1%	27	$149.70
85732		<1%	54	$128.32
85004		<1%	817	$127.91
85303		<1%	55	$123.52
85049		<1%	764	$115.60
85041		<1%	191	$104.55
86617		<1%	12	$99.49
99000		<1%	410	$97.25
82232		<1%	138	$94.92
87449		<1%	12	$84.00
85520		<1%	39	$82.89
86001		<1%	98	$76.58
83935		<1%	27	$69.29
85306		<1%	40	$67.68
86790		<1%	132	$59.09
82384		<1%	15	$44.46
84590		<1%	52	$41.24
86162		<1%	28	$36.50
86631		<1%	37	$34.65
87109		<1%	70	$27.49
82955		<1%	54	$26.20
80156		<1%	13	$25.09
82340		<1%	27	$21.77
85302		<1%	14	$21.46
87184		<1%	61	$21.21
85305		<1%	13	$20.75
82610		<1%	17	$15.10
86707		<1%	12	$14.17
86777		<1%	15	$12.79
87101		<1%	47	$12.32
85362		<1%	80	$11.70
82553		<1%	12	$10.13
82705		<1%	13	$9.06
99058		0%	696	$0.00
86005		0%	68	$0.00
86880		0%	24	$0.00
84378		0%	45	$0.00
87276		0%	13	$0.00
87280		0%	13	$0.00
87299		0%	13	$0.00
87275		0%	13	$0.00
87260		0%	13	$0.00
81241		0%	13	$0.00
87279		0%	13	$0.00
G0479	Drug test(s), presumptive, any number of drug classes; any number of devices or procedures by instrumented chemistry analyzers utilizing immunoassay, enzyme assay, tof, maldi, ldtd, desi, dart, ghpc, gc mass spectrometry), includes sample validation when performed, per date of service	0%	17	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialVARTANIAN, LALA (SECRETARY)